PHASE-II TRIAL OF CARBOPLATIN IN ADVANCED MALIGNANT-MELANOMA

  • 1 February 1987
    • journal article
    • research article
    • Vol. 71  (2) , 171-172
Abstract
Twenty-six evaluable patients with metastatic malignant melanoma who had not received prior chemotherapy were treated in a phase II study with carboplatin (CBDCA), 400 mg/m2 iv every 4 weeks. There were five partial responses of 3, 3+, 5, 7+, and 12+ months'' duration. Thrombocytopenia was the dose-limiting toxicity; ten patients had transient platelet count depressions to < 75,000/mm3. Mild to moderate nausea and/or vomiting occurred in 15 patients. Renal, auditory, and neurologic toxic effects were not encountered. Since the response rate of 19% (95% confidence limits, 8%-38%) is similar to that noted for dacarbazine, carboplatin, singly and in combination with other agents, needs further evaluation in patients with malignant melanoma.